Abeona Therap

Q2 FY2026 EarningsQ2 FY26 missed consensus expectations across most financial metrics despite a 31% QoQ increase in ZEVASKYN revenue to $11.4M (vs. $12.2M expected). Gross margin came in at 63.3%, falling short of the 70.0% consensus due to manufacturing yield challenges. Diluted EPS of -$0.35 was significantly below the -$0.23 consensus, driven primarily by a $7.2M non-cash warrant liability adjustment and the revenue miss. Management secured CMS NTAP status effective Q4 FY26, which may serve as a critical tailwind for institutional adoption.